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Abstract
Our aim was to develop and validate a predictive risk score for bronchopulmonary dysplasia (BPD), according to two clinically used
definitions: 1. Need for supplementary oxygen during ≥ 28 cumulative days, BPD28, 2. Need for supplementary oxygen at 36 weeks
postmenstrual age (PMA), BPD36. Logistic regressionwas performed in a national cohort (infants born in Switzerlandwith a birthweight
< 1501 g and/or between 23 0/7 and 31 6/7weeks PMA in 2009 and 2010), to identify predictors of BPD.We built the score as the sumof
predicting factors, weighted according to their ORs, and analysed its discriminative properties by calculating the area under the ROC
(receiver operating characteristic) curves (AUCs). This score was then applied to the Swiss national cohort from the years 2014–2015 to
perform external validation. The incidence of BPD28was 21.6% in the derivation cohort (n = 1488) and 25.2% in the validation cohort (n
= 2006). The corresponding numbers for BPD36 were 11.3% and 11.1%, respectively. We identified gestational age, birth weight,
antenatal corticosteroids, surfactant administration, proven infection, patent ductus arteriosus and duration of mechanical ventilation as
independent predictors of BPD28. The AUCs of the BPD risk scores in the derivation cohort were 0.90 and 0.89 for the BPD28 and
BPD36 definitions, respectively. The corresponding AUCs in the validation cohort were 0.92 and 0.88, respectively.
Conclusion: This score allows for predicting the risk of a very low birth weight infant to develop BPD early in life and may be
a useful tool in clinical practice and neonatal research
Keywords Bronchopulmonary dysplasia (BPD) . Prediction . Respiratory distress syndrome (RDS) . Risk score . Very low birth
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What is Known:
• Many studies have proposed scoring systems to predict bronchopulmonary dysplasia (BPD).
• Such a risk prediction may be important to identify high-risk patients for counselling parents, research purposes and to identify candidates for specific
treatment.
What is New:
• A predictive risk score for BPD was developed and validated in a large national multicentre cohort and its performance assessed by two indices of
accuracy.
• The developed scoring system allows to predict the risk of BPD development early but also at any day of life with high validity.
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Introduction
Bronchopulmonary dysplasia (BPD) is a major chronic respi-
ratory complication of preterm infants [1]. Since BPD was
described for the first time more than five decades ago [2],
perinatal care has seen major changes. In the 1960s, invasive
mechanical ventilation was the only way to manage respirato-
ry distress syndrome (RDS), and such exposure was shown to
injure premature lungs. Different therapeutic or preventive
strategies like antenatal steroids, surfactant, ventilation strate-
gies and postnatal steroids have been studied to reduce the
incidence of BPD [3, 4].
Although the administration of antenatal steroids is associ-
ated with a reduction of serious adverse outcomes related to
prematurity (perinatal and neonatal death, RDS, intraventric-
ular haemorrhage, necrotising enterocolitis), no reduction in
chronic lung disease has been shown [5]. Since the 1990s,
prophylactic surfactant therapy has dramatically improved
survival [6]. However, the analysis of studies on the routine
use of nasal continuous positive airway pressure (nCPAP)
showed a decrease in ‘BPD or death’ in infants stabilised on
nCPAP [7], rendering the practice of general prophylactic
surfactant application obsolete.
Already 20 to 30 years ago, many research groups identi-
fied risk factors and developed scoring methods to predict
BPD [8, 9]. However, those scores were rapidly outdated
due to significant changes in the management of very low
birth weight (VLBW) infants or due to changes in BPD def-
initions.More recent publications used other variables to build
new predictive scoring systems [10–12]. A 2013 systematic
review concluded that existing clinical predication models for
BPD cannot be used in practice due to low statistical quality,
and suggested that future predictive scores should be validated
before implementation [13]. A new BDP imaging score per-
formed with lung ultrasound was recently evaluated and
showed promising results [14, 15]. Risk stratification of
BPD might be useful for counselling families and clinical
trials. More importantly, it may help to identify patients at
high risk for BPD by pre-selecting them for specific treatment
approaches like postnatal steroid administration, even if the
optimal type, dosage and timing are still not well defined [16].
Our objective was to develop and validate a predictive
BPD risk score by identifying risk factors based on a national
database.
Methods
Design and data collection
This was a national multicentre registry study with prospec-
tive data collection for the development and validation of a
predictive model for BPD. Patient data were extracted from
the national database of the Swiss Neonatal Network
(SwissNeoNet), which prospectively collects data from each
of the nine Swiss neonatal intensive care units (NICUs) pro-
viding tertiary-level neonatal care. All admitted live-born in-
fants with a birth weight < 1501 g and/or gestational age
between 23 0/7 and 31 6/7 weeks postmenstrual age (PMA)
were included. Data from patients born between January 1,
2009 and December 31, 2010 were analysed as the derivation
cohort. Exclusion criteria were missing or incomplete data
sets, congenital malformations or syndromes with a potential
impact on the respiratory system, and death before fulfilling
the BPD definition, therefore not allowing the analysis of the
combined outcome ‘BPD or death’. The following variables,
considered to have a potential impact on development of
BPD, were extracted from the registry and patient records
[17]: mode of delivery, gestational age (GA), birth weight
(BW) and corresponding z-score, singleton or multiple preg-
nancy, antenatal steroid treatment, intubation in the delivery
room, significant (requiring medical or surgical treatment but
not if treated only with fluid restriction and diuretics or if
treated prophylactically in the absence of symptoms) patent
ductus arteriosus (PDA), proven infection (clinical evidence
of infection as well as at least one relevant positive blood or
cerebrospinal fluid culture), surfactant therapy, number of cu-
mulative days of mechanical ventilation (MV) and
anonymised NICUs. The outcomes predicted by the models
were BPD28 and BPD36. BPD28 was defined as the need for
supplementary oxygen (> 12 h per day) during ≥ 28 cumula-
tive days between birth and 36 weeks PMA. The criterion for
BPD36 was the need for supplementary oxygen at 36 weeks
PMA. Data from patients born between January 1, 2014 and
December 31, 2015 and included in the registry were analysed
as the validation cohort, using the same exclusion criteria and
extracting the same items as for the derivation cohort.
Statistical analysis
Data analysis was performed using STATA 14 software
(StataCorp. 2015. Stata Statistical Software: Release 14.
College Station, TX, USA). Clinical characteristics were de-
scribed by median and range for continuous variables, and
numbers and percentages for categorical variables. The asso-
ciation between risk factors and BPD was examined by
univariable logistic regression. To build the multivariable
model, a backward deletion procedure was performed. All
the variables with significant (p < 0.1) association with the
outcome from univariable analysis were entered in the initial
model. Then, variables with p value >0.05 were deleted one at
a time. Only variables with p value <0.05 were retained in the
final model. The BPD risk score was then built as the sum of
these factors and weighted according to their ORs. Internal
validation of the score was performed using the bootstrap
method (repeated 1000 times), as described by Harrell et al.
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[18]. Multicollinearity was examined using commonly used
diagnostic measures of collinearity: the Variance Inflation
Factor (VIF) and tolerance. To assess the performance of the
derived prognostic score, we examined two indices of accura-
cy: discrimination and calibration. Discrimination, i.e. the de-
gree to which the prognostic score enables the discrimination
between patients with favourable and unfavourable outcome,
was assessed by calculation of the area under the receiver
operating characteristic (ROC) curves (AUCs) in the deriva-
tion and validation cohorts. ROC analyses were performed at
36 weeks PMA and on day of life (DOL) 1. Calibration, i.e.
the agreement between predicted and actual outcome, was
assessed in the derivation and validation cohorts with the
use of the Hosmer–Lemeshow goodness-of-fit test.
Furthermore, sensitivity and specificity for the best cut-off
value were assessed. The best threshold value of the score
was chosen manually so as to simultaneously maximise the
sensitivity and specificity. This procedure was performed for
the two definitions of BPD.
Results
During the observed period for the derivation cohort (2009
and 2010), 1488 patients were born in the SwissNeoNet.
Among them, 34 were excluded because of missing data and
49 because of malformations or syndromes with potential im-
pact on the respiratory system. There were 71 deaths in the
delivery room. Finally, 102 and 109 were excluded because
they died before having reached the BPD28 and BPD36
criteria, respectively (Fig. 1a). The incidence of BPD28
among this population was 266/1232 (21.6%) and 138/1225
(11.3%) for BPD36.
The cohort used for validation (SwissNeoNet 2014–2015)
included 2006 patients. Twenty-four were excluded due to
incomplete data, 86 due to syndromes or malformations with
pulmonary impact, and 60which died in the delivery room. Of
this cohort, 103 and 112 patients did not reach the age permit-
ting a diagnosis of BPD28 or BPD36, respectively (Fig. 1b).
The incidence of BPD28 was 437/1733 (25.2%) and 191/
1724 (11.1%) for BPD36.
Calculated VIFs varied between 1.01 and 3.12 (no VIF
>10) which indicate the absence of multicollinearity between
the retained variables in the BPD28 and BPD36 BPD risk
score models.
Seven variables were identified as independent predictors
of BPD28 in a multivariable logistic regression analysis: GA,
BW, antenatal corticosteroid treatment, surfactant administra-
tion, proven infection, PDA requiring medical or surgical
treatment, and duration of MV in days. For each covariate in
the model, the β-coefficient was directly related to the corre-
sponding OR (Table 1).
The BPD28 risk score derived from the β-coefficients was
−0.40 × GA* − 0.12 × BW* − 0.51 × antenatal steroid**
+ 0.64 × PDA** + 0.85 × proven infection** + 1.15 ×
surfactant** + 1.03 × days of MV* − 2.45 (*continuous var-
iables were corrected and centrated as explained in Annex 1;
**for categorical variables—yes = 1 and no = 0).
The association between the scores and the probability to
develop BPD28 is presented in Table 2 and Fig. 2.
In the derivation cohort, maximum sensitivity (82%) and
specificity (82%) were calculated at a cut-off of − 1.4 (range −
5 to + 4) at 36 weeks PMA. At DOL 1, a cut off of − 2.2 (range
− 5.5 to + 0.8) for maximum sensitivity (81%) and specificity
(81%) was found. The BPD risk score had an excellent dis-
criminatory power, as shown by its AUC of 0.90 at 36 weeks
PMA and 0.88 at DOL 1 and was well calibrated as confirmed
by the Hosmer–Lemeshow test (Hosmer–Lemeshow χ2(28) =
24.40, Prob > χ2 = 0.66).
For the BPD36 definition, five variables were found to be
statisticaly significant: BW, surfactant administration, proven
infection, significant PDA and the sum of days of MV
(Table 3). The model built from the β-coefficients was
− 0.17 × BW* + 0.52 × PDA** + 1.29 × proven infection
+ 0.63 × surfactant** + 1.06 × days of MV* − 3.81 (*
continous variables were corrected and centrated as explained
in Annex 2; **for categorical variables—yes = 1 and no = 0).
The AUC of 0.89 at 36 weeks PMA and 0.84 at DOL 1
showed an excellent discriminatory power of the model, and
good calibration was confirmed by the Hosmer–Lemeshow
test (Hosmer–Lemeshow χ2(28) = 26.48, Prob > χ2 = 0.55).
Maximum sensitivity (83%) and specificity (83%) were cal-
culated at a cut-off of − 2.2 (range − 6 to + 2) in the derivation
cohort at 36 weeks PMA.At DOL 1, a cut off of − 3.6 (range −
6 to + 2) for maximum sensitivity (77%) and specificity (77%)
was found.
In the validation cohort, the performance of the score
showed also an excellent discriminatory power as shown by
the corresponding AUC values of 0.92 and 0.88 for BPD28
and BPD36, respectively.
As an example, for a preterm infant born at 26 3/7 weeks
PMA (GA* = − 2.81), with an incomplete course of antenatal
corticoids (antenatal steroid** = 1), a BW of 600 g (BW* = −
6.33), with 3 days of MV (MV* = −0.035), who received sur-
factant (surfactant** = 1), was treated for PDA (PDA** = 1) and
had no proven infection (infection** = 0), the score would be 0.7
and the risk of developing BPD28 would be 66.3%. If the score
was calculated for the same patient 1 week later after an addi-
tional 7 days of MV, the score would increase to 1.6 and there-
fore the probability to develop BPD would be 83%. As another
example, the BPD36 risk score for this same premature infant
born with 3 days of MV (MV* = 0.35), who received surfactant
(surfactant** = 1), and was treated for PDA (PDA** = 1) with-
out infection (infection** = 0) would be − 1.21 and the risk of
developing BPD36 would be 22.89%. This risk would increase
to 48.65% if the duration of MV increased to 10 days.
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Discussion
We developed a BPD risk score based on a large nationwide
cohort and provide validation. This score allows excellent
prediction of the risk of BPD early in life and at any time
during hospitalisation, using relatively simple data. All pre-
dictors identified by the multivariable regression are assumed
risk factors [17], except for surfactant administration and an-
tenatal steroids. The fact that surfactant was found to be a risk
rather than a protective factor in this study can be explained by
the clinical reality that its administration is a marker of disease
severity. To compare the differences in RDS support between
the nine national NICUs, we sent them a questionnaire. The
responses made it possible to consider a quite homogeneous
approach in the respiratory support of VLBW infants in
Switzerland. In time frame of the study in the vast majority
of the Swiss units, only patients with severe RDS effectively
were intubated and underwent surfactant administration,
which is in line with international guidelines for the manage-
ment of RDS [19]. Then, in the most recent Cochrane analysis
[5], antenatal steroids did not affect the risk of BPD while a
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the risk was increased in extremely preterm infants below 25
WG. In the present study, antenatal steroids only were asso-
ciatedwith reduction of BPD28 but not BPD36. Finally, lower
GA and BW, proven infection, PDA and MVwere associated
with increased risk of BPD28 while only lower BW, proven
infection, PDA andMVwere for BPD36. As in any prediction
model, accuracy of our BPD score was highest at the
timepoint when the predicted event was supposed to occur.
As the majority of our model variables are available at birth,
and our sensitivity analysis revealed reliable prediction at
DOL 1, we were able to demonstrate the validity of our score
as of DOL 1 until 36 weeks PMA, with growing accuracy
over time when more information on MV, PDA and infection
become available.
In this national cohort of preterm infants < 32 weeks PMA
and/or BW < 1501 g, the incidence of BPD varied widely
according to the definition used. The clinical diagnosis of
BPD is often used for quality control and benchmarking be-
tween NICUs [21, 22], and for the evaluation of new preven-
tive and therapeutic strategies [23, 24]. Unfortunately, the lat-
est consensus definition of BPD [25] is still not uniformly
used in the recent literature. This is probably due to two of
its shortcomings: (1) the definition requires an accurate num-
ber of hours (>12 h/day) and days of oxygen dependency, data
Table 1 Univariate and multivariate logistic regression analysis for the BPD28 definition
Clinical characteristics Prevalence Univariate Multivariate β-
coefficient
BPD (+) BPD (−) BPD (+) BPD (+)






















































6.23 < 0.0001 1.90 < 0.0001 0.64
BPD bronchopulmonary dysplasia, BW birth weight, GA gestational age, MV mechanical ventilation, PDA patent ductus arteriosus
Table 2 Probability of developing BPD28 according to the BPD risk
score











Fig. 2 Correlation between the BPD risk score and the probability of
developing BPD28. Frequency: number of patients in the validation
cohort; risk of BPD: probability of developing BPD28
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which may be difficult to obtain in clinical practice and may
not be systematically collected in patient records; and (2) in
the National Institute of Child Health and Human
Development (NICHD) consensus definition of BPD,
nCPAP use is not considered as a possible substitute for sup-
plemental oxygen administration and, therefore, the duration
of nCPAP use is not considered in our algorithm. However, a
higher mean airway pressure reduces oxygen requirement. It
should be noted that nCPAP was the favoured primary mode
of respiratory support in most Swiss units during the study
period. According to the BPD36 definition, all infants treated
with nCPAP at 36 weeks PMA would not be considered as
having BPD if FiO2 is 0.21 (i.e. room air). If such an infant
received more than 28 cumulative days of oxygen between
birth and 36 weeks PMA, it would however fullfil the criteria
of BPD28. Such incoherencies may in part explain the large
differences between BPD incidences in the literature [26] and
in our study (25.2% vs. 11.1% in the validation cohort for
BPD28 and BPD36, respectively). The definition of BPD36
as used in this study may therefore be considered as a surro-
gate for moderate to severe forms of BPD28, according to the
NICHD consensus definition.
Until now, as mentioned by Onland et al. [13], most pub-
lished BPD scoring systems are only poor to moderate predic-
tors of BPD because most of them lack validation [8, 12, 27,
28]. Furthermore, there is no published study presenting a
calibration assessment of the model. In the present study,
two indices of accuracy were used to assess the performance
of the score. The discrimination power evaluated by the AUC
was excellent and good calibration was confirmed by the
Hosmer–Lemeshow test for both definitions in the derivation
and validation cohorts. Otherwise, in most studies, scores as-
sess the risk of developing BPD only at a particular moment.
For example, Sinkin et al. [8] suggested a prediction at 12 h or
10 DOL, whereas Rozycki et al. [9] proposed an evaluation at
8 h of life or 14 DOL. In the study by Laughon et al. [12],
prediction was made at the specific DOL 1, 3, 7, 14, 21 or 28.
Compared to the Laughon score [12], our BPD score has
several advantages: (1) it is based on easily assembled param-
eters available at any DOL until 36 weeks PMA; (2) infants of
derivation and validation cohorts received comparable RDS
management strategy promoting nCPAP over MV and are
thus closer to typical modern day neonates; (3) the perfor-
mance of the score is not only assessed by discrimination
power but also by a calibration method. Promising new
predicting imaging strategies using lung ultrasound are
emerging [14, 15]. It would be interesting to compare this
method with our model or to evaluate if the combination of
both tools adds value to BPD prediction. The advantage of our
score is that it is quickly achieved with existing data, and that
it does not require performing lung ultrasounds, which may
not be available in every NICU. Another strength of our study
is its high number of patients, representing a whole popula-
tion. SwissNeoNet includes > 97% of very preterm babies
born in the country where patients are managed according to
the best current standards with high rate of antenatal steroid
treatments and preventive nCPAP. AUCs above 0.88
achieved in derivation and validation cohorts for both defini-
tions allow an excellent prediction. Moreover, external vali-
dation brings more value to the results.
Our study presents some limitations. First, the data are
extracted from a registry. Then, the scoring system was based
on data coming from a country with lower BPD rate than
reported internationally [29] with a quite homogeneous ap-
proach regarding respiratory support among the included ter-
tiary centers. This model may not be applicable with the same
Table 3 Univariate and
multivariate logistic regression
analysis for the BPD36 definition
Clinical characteristics Prevalence Univariate Multivariate β-
coefficient
BPD (+) BPD (−) BPD (+) BPD (+)
OR P value OR P value
TOTAL n
(%)



































6.95 < 0.0001 3.62 < 0.0001 1.29
BPD bronchopulmonary dysplasia, BW birth weight, MV mechanical ventilation, PDA patent ductus arteriosus
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accuracy in different settings. In addition, other variables with
a potential impact on BPD such as gender or ethnicity were
not included in the analysis. A further drawback is that the
formula, due to its complexity, requires a calculator. To facil-
itate the use of the BPD risk score, we provide a web-based
calculator at the following link: http://calc.chuv.ch/.
In conclusion, the presented BPD risk score allows to pre-
dict early in life and at any DOL the risk for a preterm infant to
develop BPD and its potential to be moderate to severe by
using seven or five easily available variables, respectively.
This BPD risk score may be a useful tool in clinical practice
and in neonatal research for the early identification and strat-
ification of patients with a high risk of BPD.
Annex 1
Coding: continuous variables for BPD28 definition
Days of mechanical ventilation (MV):
X = (days of MV + 1)/100
MV1 = (X−1) − 20.99880689
MV2 = (X−0.5) − 4.582445514
MV3 = 0.0582029 × MV1 − 0.9061262 × MV2
Days of MV* = MV3 + 0.11
Gestational age (GA):
GA (days) = 7 × GA (weeks) + GA (days)
GA1 = GA (days)/7
GA* = GA1 − 29.24
Birth weight (BW):
BW* = BW (g)/100 − 12.33
Annex 2
Coding: continous variables for BPD36 definition
Days of mechnical ventilation (MV):
X = (days of MV + 1)/100
MV1 = (X−1) − 21.58210007
MV2 = (X−1) × ln(X) + 66.29728209
MV3 = − 0.2402667 × MV1 − 0.0451578 × MV2
Days of MV* = MV3 + 0.53
Birth weight (BW):
BW* = BW (g)/100 − 12.33
Abbreviations AUCs, Area under the receiver operating characteristic
curves; BPD, Bronchopulmonary dysplasia; BW, Birth weight; DOL,
Day of life; GA, Gestational age; MV, Mechanical ventilation; nCPAP,
Nasal continuous positive airway pressure; NICHD, National Institute of
Child Health and Human Development; NICUs, Neonatal intensive care
units; PDA, Patent ductus arteriosus; PMA, Postmenstrual age; RDS,
Respiratory distress syndrome; ROC, Receiver operating characteristic;
SwissNeoNet, Swiss Neonatal Network; VIF, Variance Inflation Factor;
VLBW, Very low birth weight
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